泰凌医药(01011.HK) 公布，向8名独立第三方间接收购浙江康源医疗器械58.11%股权，代价1.16亿人民币(约1.24亿港元)，将透过发行2.74亿股代价股支付，发行价0.45元，较上交易日(28日)收报折让22.41%。浙江康源医疗器械于内地从事研发及经营X射线机器人骨密度系统及便携式数字X射线诊断机器人系统，持有12个相关专利及25个原代码。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.